Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Retained Earnings: 2010-2025

Historic Retained Earnings for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to -$2.7 billion.

  • Iovance Biotherapeutics' Retained Earnings was N/A to -$2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 billion, marking a year-over-year change of. This contributed to the annual value of -$2.4 billion for FY2024, which is 18.49% down from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Retained Earnings stood at -$2.7 billion, which was down 3.49% from -$2.6 billion recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Retained Earnings high stood at -$1.7 billion for Q1 2023, and its period low was -$2.7 billion during Q3 2025.
  • In the last 3 years, Iovance Biotherapeutics' Retained Earnings had a median value of -$2.1 billion in 2024 and averaged -$2.2 billion.
  • Data for Iovance Biotherapeutics' Retained Earnings shows a maximum YoY decreased of 26.83% (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Retained Earnings (Quarterly) stood at -$2.0 billion in 2023, then dropped by 18.49% to -$2.4 billion in 2024, then declined by 17.66% to -$2.7 billion in 2025.
  • Its last three reported values are -$2.7 billion in Q3 2025, -$2.6 billion for Q2 2025, and -$2.5 billion during Q1 2025.